Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
2.800
-0.150 (-5.08%)
At close: Nov 20, 2024, 4:00 PM
2.820
+0.020 (0.71%)
Pre-market: Nov 21, 2024, 7:12 AM EST
Autolus Therapeutics Employees
As of December 31, 2023, Autolus Therapeutics had 471 total employees, including 463 full-time and 8 part-time employees. The number of employees increased by 67 or 16.58% compared to the previous year.
Employees
471
Change (1Y)
67
Growth (1Y)
16.58%
Revenue / Employee
$21,425
Profits / Employee
-$573,730
Market Cap
745.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Healthcare Services Group | 33,400 |
Avanos Medical | 3,771 |
Embecta | 2,200 |
Castle Biosciences | 610 |
AbCellera Biologics | 586 |
Relay Therapeutics | 323 |
Liquidia | 145 |
Cullinan Therapeutics | 85 |
AUTL News
- 8 hours ago - AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market - Seeking Alpha
- 8 days ago - Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - GlobeNewsWire
- 23 days ago - Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - GlobeNewsWire
- 2 months ago - Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case - Seeking Alpha
- 3 months ago - Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 - GlobeNewsWire
- 5 months ago - Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress - GlobeNewsWire